Achilles Therapeutics plc

NASDAQ:ACHL

0.71 (USD) • At close September 18, 2024
Bedrijfsnaam Achilles Therapeutics plc
Symbool ACHL
Munteenheid USD
Prijs 0.71
Beurswaarde 29,172,410
Dividendpercentage 0%
52-weken bereik 0.63 - 1.76
Industrie Biotechnology
Sector Healthcare
CEO Dr. Iraj Ali
Website https://www.achillestx.com

An error occurred while fetching data.

Over Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in

Vergelijkbare Aandelen

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

CTMX

1.19 USD

Anixa Biosciences, Inc. logo

Anixa Biosciences, Inc.

ANIX

3.45 USD

Selecta Biosciences, Inc. logo

Selecta Biosciences, Inc.

SELB

0.881 USD

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.69 USD

Rezolute, Inc. logo

Rezolute, Inc.

RZLT

4.87 USD

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

TCRT

3.12 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

14.17 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)